News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Dr. Reddy’s Laboratories Ltd.'s FY09 Revenues at Rs. 69,441 Million, EBITDA at Rs. 14,505 Million
May 18, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (NYSE:RDY) today announced its unaudited financial results for the year ended March 31, 2009 under International Financial Reporting Standards (IFRS).
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Asia
MORE ON THIS TOPIC
Layoff Tracker
Alltrna’s Clinical Acceleration Aims Leave 35% of Staff Behind
March 6, 2026
·
31 min read
·
BioSpace Editorial Staff
Cardiovascular disease
Alnylam Unites With Tenaya in Potential $1B+ Pact To Find New Genetic Heart Disease Targets
March 5, 2026
·
2 min read
·
Heather McKenzie
Collaboration
Roche Broadens Global Clinical Trial Footprint With $480M+ South Korea Pledge
March 5, 2026
·
1 min read
·
Tristan Manalac
Podcast
UniQure’s Delay, REGENXBIO’s Rejection Explained, Sarepta’s Ingram Steps Down, More
March 4, 2026
·
1 min read
·
Heather McKenzie
